Compare RELL & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RELL | MSLE |
|---|---|---|
| Founded | 1947 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Electronic Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3M | 146.9M |
| IPO Year | 2004 | N/A |
| Metric | RELL | MSLE |
|---|---|---|
| Price | $17.79 | $6.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 319.4K | 25.8K |
| Earning Date | 04-08-2026 | N/A |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $208,909,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.79 | $5.50 |
| 52 Week High | $19.86 | $13.39 |
| Indicator | RELL | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 45.58 |
| Support Level | $10.10 | $6.71 |
| Resistance Level | $19.86 | $8.59 |
| Average True Range (ATR) | 1.56 | 0.40 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 56.79 | 26.53 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.